Key Highlights

  • Reported net sales were USD 207.9 million, up 2.3% year over year.
  • Adjusted EBITDA was USD 26 million, or 12.5% of pro forma net sales.
  • Global Limb Reconstruction net sales were USD 36.4 million, up 9% in constant currency.
  • Full year pro forma net sales guidance is USD 825 million to USD 830 million.

Orthofix Medical Inc. (NASDAQ:OFIX) reported third quarter 2026 net sales of USD 207.9 million, an increase of 2.3% from the prior year. Reported EPS was negative USD 0.15, compared with estimates of EPS of negative USD 0.27 and Revenue of USD 210.52 million. Growth rates cited on the call are on a pro forma constant currency basis and exclude the discontinued M6 artificial disc product lines.

Non-GAAP adjusted gross Margin was 70.7%, which the company tied to unfavorable geographic mix. Adjusted EBITDA was USD 26 million, or 12.5% of pro forma net sales, compared with USD 24.6 million, or 12.1%, in the prior year period. The company ended the quarter with USD 86.9 million in cash, cash equivalents and restricted cash.

Franchise Performance

Global Spinal Implants, Biologics and Enabling Technologies generated USD 107.4 million in net sales, a decrease of approximately 1%. Global Spine Fixation net sales increased 1% in constant currency, while U.S. Spine Fixation declined 5%. Management said supplier delays and instrument set constraints limited the company's ability to consistently support Demand among its top 30 distributors, whose pace of growth weakened but remains above the market.

Therapeutic Solutions generated USD 64 million in net sales, up 4%. Within Therapeutic Solutions, management cited 4% Volume growth, above market growth, with attractive margins and cash generation. Global Limb Reconstruction net sales were USD 36.4 million, up 9% in constant currency, with FITBONE and TrueLok Elevate each growing in excess of 20%.

Product and Distribution Developments

The company received two 510(k) clearances in the quarter for additional software enhancements to the 7D navigation system. In September, it submitted a 510(k) premarket notification for an automated version of the TrueLok Elevate system. In bone growth stimulation, management said the priority is improving prescription conversion using digital capabilities including AccelStim 2.0 and STIM onTrack.

Chief executive Massimo Calafiore described the move toward core distribution partners and said the consigned Assets of those partners turn around 20% faster than the loaner-heavy model used by many distributors the company is exiting.

Guidance and 2027 Considerations

The company now projects full year 2026 pro forma net sales of USD 825 million to USD 830 million and non-GAAP adjusted EBITDA of USD 86 million to USD 88 million. For the fourth quarter, management cited sequential growth from normal seasonality and inventory purchases under the European distributor arrangement.

Most of the approximately USD 15 million 2026 net sales benefit from the European distributor arrangement is projected to be recognized in the fourth quarter. The arrangement creates a temporary free cash timing headwind in 2026, because inventory-related cash outflows occur this year while cash receipts are scheduled for 2027.

The company said it provides formal 2027 guidance on its fourth quarter call. It also noted that its European MDR strategy for Spine creates an approximately USD 22 million net sales headwind in 2027 while MDR requirements are completed.

Guidance and Product Pipeline

Orthofix's pro forma net sales guidance for 2026 is USD 825 million to USD 830 million. Management cited fourth quarter timing for the European distributor benefit, the status of the TrueLok Elevate 510(k) submission, formal 2027 guidance scheduled for the next earnings call, and the VIRATA platform and 7D navigation system in the spine franchise.